Cellectar Biosciences Reports 2025 Financial Results and Corporate Highlights: Major Regulatory and Pipeline Advances

Summary

• Submission of Conditional Marketing Authorization (CMA) for lead drug iopofosine I-131 to European Medicines Agency (EMA) on track for Q3 2026, targeting potential 2027 commercialization in EU for Waldenström Macroglobulinemia (WM).
• Breakthrough Therapy Designation (BTD) granted by U.S. FDA for iopofosine I-131 in relapsed/refractory WM, with regulatory guidance to expand investigation into post-BTKi settings, potentially increasing U.S. market reach.
• Initiated Phase 1b trial of CLR 125 for triple negative breast cancer (TNBC), with early data anticipated by mid-2026.
• Significant reductions in R&D and G&A expenses year-over-year, extending cash runway into Q3 2026.
• Net loss narrowed substantially to \$21.8 million from \$44.6 million in 2024.
• Expanded intellectual property estate and secured critical supply agreements to support next-generation radiotherapeutic programs.

Detailed Analysis and Investor-Relevant Developments

1. Regulatory and Pipeline Progress

Iopofosine I-131 (Lead Asset)

• Cellectar is preparing to submit a Conditional Marketing Authorization (CMA) application to the EMA in Q3 2026 for iopofosine I-131 as a treatment for Waldenström Macroglobulinemia (WM), with targeted EU launch in 2027. The submission will leverage data from the pivotal CLOVER WaM study, including robust 12-month follow-up, response rates, progression-free survival, duration of response, and subset analyses for post-BTKi patients.
• The U.S. FDA granted Breakthrough Therapy Designation (BTD) for iopofosine I-131 in relapsed/refractory WM, which is a significant regulatory milestone that can expedite development and review. The FDA also recommended studying the drug in post-BTKi settings as early as second-line therapy, potentially expanding its U.S. market opportunity.

CLR 125 (Next-Generation Radiotherapeutic)

• Initiated Phase 1b dose finding study in triple negative breast cancer (TNBC), with enrollment ongoing and early data expected by mid-2026. This study will evaluate three dosing regimens to determine the recommended Phase 2 dose, with primary endpoints of safety, tolerability, and initial efficacy (RECIST v1.1 and PFS).
• Preclinical studies demonstrated favorable safety (no end-organ or hematologic toxicity) and significant solid tumor reduction/inhibition.
• Cellectar secured a supply agreement with Ionetix for commercial-scale production of Actinium-225 (Ac-225) and Astatine-211 (At-211), ensuring access to critical radioisotopes for current and future development programs.

Intellectual Property & Platform Expansion

• Cellectar strengthened its global IP position, gaining new patents across Europe, Asia-Pacific, Middle East, and the Americas, covering iopofosine I-131 and the broader radiotherapeutic pipeline, including CLR 125.

2. Financial Overview

• Cash and cash equivalents stood at \$13.2 million as of December 31, 2025, down from \$23.3 million a year earlier. Management anticipates this will fund baseline operations through Q3 2026.
• R&D expenses dropped to \$11.5 million (from \$26.1 million in 2024), with the decrease primarily due to the transition of the CLOVER WaM study into the follow-up phase and completion of manufacturing pipeline redundancies.
• G&A expenses fell to \$11.5 million (from \$25.6 million), reflecting reduced pre-commercialization activities and lower headcount.
• Other income, mainly from non-cash warrant valuation changes, was \$1.2 million versus \$7.3 million in the prior year.
• Net loss for 2025 was \$21.8 million, or \$8.35 per basic/diluted share, a substantial improvement from a \$44.6 million net loss (\$36.52 basic/\$41.89 diluted per share) in 2024. The reduction in loss is due to lower operating expenses and stabilized other income/expenses.
• Total assets at year-end were \$15.0 million, with \$4.7 million in current liabilities, \$1.4 million mezzanine equity, and \$8.5 million in stockholders’ equity.

3. Additional Corporate Developments

• The company’s proprietary Phospholipid Drug Conjugate™ (PDC) platform is being leveraged for additional assets, including the actinium-225 based CLR 225 and other preclinical/partnered PDC programs, targeting high unmet needs such as pancreatic cancer.
• Cellectar is eligible for a Pediatric Review Voucher from the FDA upon approval of iopofosine I-131 for pediatric high-grade gliomas, enhancing potential future value.
• The company has received multiple regulatory designations (Breakthrough, Orphan Drug, Rare Pediatric Drug, Fast Track, and PRIME) for iopofosine I-131 across several indications, which can facilitate faster development and regulatory review.

4. Shareholder/Price Sensitive Considerations

• Upcoming EMA CMA application for iopofosine I-131 and potential 2027 EU commercialization.
• FDA Breakthrough Therapy Designation and expanded clinical pathway for U.S. market — increases probability of approval and market size.
• Positive early data from CLR 125 in TNBC expected mid-2026 — success could unlock a new high-value indication.
• Improved financial discipline, cash runway into Q3 2026 — reduces near-term dilution risk, but additional capital will likely be needed for pivotal trials and commercialization.
• Broadened IP and secured supply agreements for key isotopes — de-risks future pipeline development.

Conclusion

Cellectar Biosciences delivered notable regulatory, clinical, and operational progress in 2025, positioning its lead and next-generation assets for pivotal milestones in the coming 12-24 months. The upcoming EMA submission for iopofosine I-131, new FDA designations, and advancing radiotherapeutic pipeline could act as significant catalysts for the company’s valuation. Investors should monitor the company’s ability to secure additional capital, as the current cash runway extends only into Q3 2026. Overall, the developments disclosed are material and potentially price-sensitive, with multiple near-term inflection points.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation regarding the securities of Cellectar Biosciences, Inc. Investing in biotechnology companies involves significant risk, including the potential loss of principal. Readers should conduct their own due diligence and consult with a financial advisor before making investment decisions. All information is based on company disclosures as of March 4, 2026, and may be subject to change without notice.

View Cellectar Biosciences, Inc. Historical chart here